Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that it has enrolled ...

The CEO of GH Research, Dr. Velichka Valcheva, pointed out that the response addressed the FDA’s requests with comprehensive ...

A study has developed a reliable way to measure whether seriously ill hospitalized patients receive medical care that aligns ...

According to an SEC filing dated July 2, 2025, LVM Capital Management reduced its position in ICON Public Limited ( ICLR 1.86 ...

John Houston, Ph.D., Chairperson, CEO and President at Arvinas, Announces Plans to Retire as CEO Upon Appointment of ...

Rahway, New Jersey Wednesday, July 9, 2025, 13:00 Hrs [IST] ...

Some two dozen biotech developers of PROTACs, molecular glues and other types of protein-degrading drugs have sprung up over ...

Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform ...

TURKU, FI / ACCESS Newswire / July 9, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - The oral presentation and poster showcase bexmarilimab's dual attack on cancer with new mechanistic data from ...

Newly issued U.S. composition of matter patent expected to provide exclusivity into 2042, with subsequent opportunity for patent term extension - ...

Cancer Research UK has awarded £457,000 to support a pioneering study in Cambridge that could play a pivotal role in the ...